Cost Utility Analysis of 177Lu-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC) in Germany

被引：0
|
作者：
Stargardt, T. [1 ]
Brinkmann, C. [1 ]
Baum, R. P. [2 ,3 ]
机构：
[1] Univ Hamburg, Hamburg Ctr Hlth Econ, Hamburg, Germany
[2] Int Ctr Precis Oncol ICPO, Wiesbaden, Germany
[3] CURANOSTICUM, Wiesbaden, Germany
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0988
引用
收藏
页码：S827 / S827
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness Analysis of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Mehrens, Dirk
    Kramer, Kristina K. M.
    Unterrainer, Lena M.
    Beyer, Leonie
    Bartenstein, Peter
    Froelich, Matthias F.
    Tollens, Fabian
    Ricke, Jens
    Ruebenthaler, Johannes
    Schmidt-Hegemann, Nina-Sophie
    Herlemann, Annika
    Unterrainer, Marcus
    Kunz, Wolfgang G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2023, 21 (01): : 43 - +
  • [2] Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Aggarwal, Piyush
    Gunasekaran, Vinisha
    Sood, Ashwani
    Kumar, Narendra
    Rathore, Yogesh
    Kumar, Rajender
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (03) : 231 - 233
  • [3] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [4] Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
    Mader, Nicolai
    Schoeler, Christina
    Pezeshkpour, Niloufar
    Klimek, Konrad
    Groener, Daniel
    Happel, Christian
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (18)
  • [5] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [6] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [7] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [8] Comment on, 177Lu-PSMA-617 in metastatic, castration-resistant prostate cancer"
    Radtke, Jan Philipp
    Albers, Peter
    Giesel, Frederik Lars
    AKTUELLE UROLOGIE, 2022, 53 (02)
  • [9] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Fadi Khreish
    Niklas Kochems
    Florian Rosar
    Amir Sabet
    Martin Ries
    Stephan Maus
    Matthias Saar
    Mark Bartholomä
    Samer Ezziddin
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 103 - 112
  • [10] Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy
    Khreish, Fadi
    Kochems, Niklas
    Rosar, Florian
    Sabet, Amir
    Ries, Martin
    Maus, Stephan
    Saar, Matthias
    Bartholomae, Mark
    Ezziddin, Samer
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2021, 48 (01) : 103 - 112
12345